Well Referenced

Tag: gastrointestinal side effects

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

The 2023 OASIS 1 trial evaluated the efficacy and safety of oral semaglutide 50 mg daily in 667 adults with overweight or obesity without type 2 diabetes. Over 68 weeks, participants receiving semaglutide experienced a mean weight loss of 15.1%, compared to 2.4% with placebo. Notably, 85% of the semaglutide

Read More »
June 26, 2025 No Comments

Tirzepatide Once Weekly for the Treatment of Obesity

This 2022 randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) over 72 weeks in 2,539 adults with obesity or overweight with at least one weight-related comorbidity, excluding diabetes. Participants receiving tirzepatide experienced significant, dose-dependent weight reductions: −15.0% with

Read More »
June 26, 2025 No Comments

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial

The STEP 8 trial was a 68-week, randomized, double-blind, double-dummy, phase 3 clinical study comparing once-weekly subcutaneous semaglutide 2.4 mg to once-daily subcutaneous liraglutide 3.0 mg in 338 adults with overweight or obesity without diabetes. Participants received lifestyle interventions alongside medication. Semaglutide led to a greater mean weight loss (−15.8%)

Read More »
June 26, 2025 No Comments

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

This 2-year randomized, double-blind, placebo-controlled trial assessed the long-term safety, tolerability, and efficacy of once-daily subcutaneous liraglutide (1.2–3.0 mg) in 564 obese adults (BMI 30–40 kg/m²) across 19 European centers. After a 20-week core phase, 398 participants entered a 2-year extension. At 1 year, those on liraglutide 3.0 mg lost

Read More »
June 26, 2025 No Comments

Clinical utility of curcumin extract

This review explores the potential therapeutic benefits of curcumin, the active compound in turmeric, highlighting its anti-inflammatory, antineoplastic, and antioxidant properties. Curcumin has shown promise in treating conditions such as dyspepsia, peptic ulcer, inflammatory bowel disease, rheumatoid arthritis, osteoarthritis, uveitis, orbital pseudotumor, and pancreatic cancer. Its mild side effects, including

Read More »
June 26, 2025 No Comments

Inflammation, Frailty and Cardiovascular Disease

This meta-analysis demonstrated that subcutaneous semaglutide significantly reduced body weight by up to 14.9%, improved glycemic control with an average HbA1c reduction of 1.7%, and had a manageable safety profile dominated by gastrointestinal side effects. It involved over 1,961 participants, predominantly adults with obesity, and highlighted semaglutide’s potential to enhance

Read More »
June 26, 2025 No Comments